Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel
NASDAQ:ALT

Altimmune Q3 2026 Earnings Date & Estimates

Altimmune logo
$2.32 +0.01 (+0.22%)
As of 02:34 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Altimmune is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Altimmune in Q3 2026

Altimmune is expected to post earnings of -$0.14 per share on revenue of $0.00 million. In the same quarter a year earlier Altimmune reported -$0.21 per share on revenue of $0.01 million. Altimmune last reported on August 12, 2026, posting -$0.12 per share and beating the -$0.1355 consensus estimate. Altimmune has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.14
Expected Revenue
$0.00 million
Prior-Year EPS
-$0.21
Prior-Year Revenue
$0.01 million
Expected Revenue Growth
-60.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.12 (Beat by +$0.0155)
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Altimmune Q3 2026 Earnings FAQ

Altimmune (NASDAQ:ALT) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Altimmune's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Altimmune to post earnings of -$0.14 per share for Q3 2026.

The consensus revenue estimate for Altimmune is $0.00 million for Q3 2026.

Altimmune Earnings Headlines

Altimmune, Inc. (ALT) Stock Earnings Call Transcripts - Yahoo Finance
October 14 at 8:35 AM  |  finance.yahoo.comhttps://finance.yahoo.com/quote/ALT/earnings-calls/
Altimmune consensus price target increased by 16.59% to MX$328.82
October 4, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/altimmune-consensus-price-target-increased-by-16-59-to-mx-328-82/ar-AA2dyu0H
Buffett's Final Warning: "The Dollar Is Going to Hell"
On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.tc pixel
October 15 at 1:00 AM  |  Decentralized Masters (Ad)
Altimmune no Stifel 2026 Virtual Cardiometabolic Forum: aposta no fígado
September 30, 2026  |  br.investing.comhttps://br.investing.com/news/transcripts/altimmune-no-stifel-2026-virtual-cardiometabolic-forum-aposta-no-figado-93CH-2079728
Altimmune en el Foro Virtual Cardiometabólico Stifel 2026: apuesta por el hígado
September 30, 2026  |  mx.investing.comhttps://mx.investing.com/news/transcripts/altimmune-en-el-foro-virtual-cardiometabolico-stifel-2026-apuesta-por-el-higado-93CH-3781999
Altimmune, Inc. Announces Appointment of Richard Menziuso as Global Controller and Principal Accounting Officer, Effective September 29, 2026
September 30, 2026  |  marketscreener.comM
See More Altimmune Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Altimmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Altimmune and other key companies, straight to your email.

About Altimmune

Altimmune (NASDAQ:ALT) (NASDAQ:ALT) is a clinical-stage biotechnology company developing peptide-based therapeutics for metabolic and liver diseases. The company’s lead product candidate is pemvidutide, an investigational dual GLP-1 and glucagon receptor agonist being studied for chronic weight management and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH).

Altimmune’s development programs are focused on addressing obesity, related metabolic conditions and chronic liver disease. Pemvidutide is designed to combine effects on appetite, body weight and metabolic health, and the company evaluates its potential through clinical studies. As an investigational medicine, its safety and effectiveness remain subject to ongoing clinical research and regulatory review.

Headquartered in Gaithersburg, Maryland, Altimmune conducts its research and development activities primarily through clinical programs and collaborations supporting the advancement of its therapeutic candidates. The company is led by Vipin K. Garg, Ph.D., who serves as president and chief executive officer.

View Altimmune Profile
Earnings Tools